The Serious Case of Canaglifozin & Dapagliflozin. Canagliflozin and dapagliflozin are sodium-glucose co-transporter 2 (SGLT2) inhibitors that together with diet and exercise help lower blood glucose in adults with type 2 diabetes. These medications decrease blood glucose by causing the kidneys to remove sugar from the body through the urine, reports MPR News.
A strengthening of the current warning about the dangers of acute kidney injury involving certain diabetes medications was announced by the U.S. Food and Drug Administration (FDA).
Drugs containing canagliflozin, (trade names Invokana and Invokamet) and dapagliflozin (brand names Farxiga and Xigkuo XR) have received modification in the drug labeling.
The stronger warning informs consumers of acute kidney injury risks as well as recommendations to minimize this risk.
Canagliflozin was approved and through October 2015
In March 2013, canagliflozin was approved and through October 2015, the FDA has received 101 reports of cases of acute kidney injury. Of those cases, 73 were related to canagliflozin, and 28 with canagliflozin or dapagliflozin use.
Hospitalization was required for 96 cases, 22 of which had to be admitted to the intensive care unit. There were 4 deaths reported during hospitalization.
Dialysis was required in 15 patients, 3 of whom had a history of chronic kidney disease or previous acute kidney issues. Approximately half of the reported cases of acute kidney injury occurred within one month of beginning the drug. Most patients improved upon discontinuing the medication, according to MPR News.
Patients and healthcare providers are advised to look for the signs and symptoms of acute kidney injury which may include decreased urine or swelling in the legs or feet.